$MEDP

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

UBS raised its price target on Medpace to $700 from $673 while maintaining a neutral rating. The stock is currently trading at $666.52, up 1.92% today and 7.35% year-to-date. Truist Securities also adjusted its target to $633 from $609, keeping a hold rating.

TD Cowen kept a Hold rating on Medpace Holdings with a $673 price target, a 2.9% upside from the Oct 22 close. Analysts cite strong demand for CROs, but balanced risks like cancellations and margin pressures.

Medpace Holdings' average stock price target increased from $614.75 to $624.33 by 12 analysts, with a range of $492 to $700. This implies a 6% downside from the Oct. 21 closing price. The consensus rating remains 'Hold' among 16 analysts.

Medpace Holdings, Inc. (MEDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Contact: David Ruhe 283-227-6472 d.ruhe@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 283-227-6367 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2026 Results • Revenue of $716.0 million in the third quarter of 2026 increas

Medpace Holdings Inc. reports Q3 earnings with analysts expecting $4.44 EPS on $714.47M revenue, up from Q2. The company trades at $622.43 with a market cap of $17.4B. Analysts have a neutral consensus rating and a mean price target of $595.92. Investors will watch bookings momentum and backlog growth, which stood at $3.01B in Q2. Medpace's premium valuation and AI disruption are also key concerns.

Beyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.

Medpace Holdings Inc (MEDP) shares fell 4.2% to $598.08, within a 52-week range of $373.00 to $677.90. The stock is overvalued by 11.3% according to GF Value™, with a GF Score™ of 97/100. Insiders sold $436.7M in shares over the past year, with no purchases. The P/E ratio is 35.1x, above its 5-year median of 31.5x.

Medpace's President & CEO August J. Troendle sold 49,100 shares in two transactions on 2026-09-29 and 2026-09-30, totaling $30.3M. He now directly owns 338,225 shares and indirectly owns 4.7M shares via Medpace Investors, LLC, according to SEC filings.

Troendle August J. (President & CEO) sold 48,667 shares of Medpace Holdings, Inc. (MEDP) at an average of $623.03 ($621.02–$625.47, $30.32M total) across 2 trades over 2026-09-29 to 2026-09-30.